More than a majority of cancer patients do not understand that if they enter into a clinical trial they have no guarantee that they will receive the investigational treatment that they believe their doctor wants them to receive! More transparent clinical trial consenting procedures need to be immediately instituted.
The gold standard of clinical trial end points is survival. Since prostate cancer tends to move relatively slowly it can take many years for a clinical trial to be completed. We need better surrogate endpoints for survival so that trials can be completed more quickly allowing new drugs to flow to us.